FORM D



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM D

MAY I 9 NUO3

SEC US	SE ONLY
Prefix	Serial
DATE R	RECEIVED

NOTICE OF SALE OF SECURITIE	S
PURSUANT TO REGULATION D	18
PURSUANT TO REGULATION D SECTION 4(6), AND/OR	//

UNIFORM LIMITED OFFERING EXEMPTION lame of Offering: (check if this is an amendment and name has changed, and indicate change.)

PharmaNetics, Inc. – 2003 Sale of Series B Convertible Preferred Stock and Warrants Filing Under (Check box(es) that apply): ☐ Rule 504 ☐ Rule 505 □ Rule 506 ☐ ULOE Section 4(6) ☐ Amendment Type of Filing: New Filing A. BASIC IDENTIFICATION DATA 1. Enter the information requested about the issuer Name of Issuer (check if this is an amendment and name has changed, and indicate change.) PharmaNetics, Inc. Address of Executive Offices (Number and Street, City, State, Zip Code) Telephone Number (Including Area Code) 9401 Globe Center Drive, Suite 140, Morrisville, North Carolina 27560 (919) 582-2600 Address of Principal Business Operations (Number and Street, City, State, Zip Code) Telephone Number (Including Area Code) (if different from Executive Offices) Brief Description of Business A publicly traded holding company for Cardiovascular Diagnostics, Inc., a medical device company. Type of Business Organization orporation limited partnership, already formed other (please specify): limited partnership, to be formed

Actual or Estimated Date of Incorporation or Organization:

Month

Year 9 8

☐ Estimated

MAY 202003

Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State:

CN for Canada; FN for other foreign jurisdiction)

N C

THOMSON FINANCIAL

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

0

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

A. BASIC IDENTIFICATION DATA 2. Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. ☐ Promoter ☐ Beneficial Owner General and/or Check Box(s) that Apply: Executive Officer □ Director Managing Partner Full Name (Last name first, if individual) Funkhouser, John P. Business or Residence Address (Number and Street, City, State, Zip code) 9401 Globe Center Drive, Suite 140, Morrisville, North Carolina 27560 Check Box(s) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer □ Director General and/or Managing Partner Full Name (Last name first, if individual) Puckett, Stephen R. Business or Residence Address (Number and Street, City, State, Zip code) Medcath, 10720 Sikes Place, Suite 300, Charlotte, North Carolina 28277 Check Box(s) that Apply: ☐ Promoter ☐ Beneficial Owner Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Tracy, Philip R. Business or Residence Address (Number and Street, City, State, Zip code) Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, 150 Fayetteville Street Mall, Suite 2500, Raleigh, North Carolina 27601 Check Box(s) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Pirotte, John K. Business or Residence Address (Number and Street, City, State, Zip code) 14240 Wyndfield Circle, Raleigh, North Carolina 27615 ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer □ Director ☐ General and/or Check Box(es) that Apply: Managing Partner Full Name (Last name first, if individual) Tuttle, Frances L. Business or Residence Address (Number and Street, City, State, Zip code) Bayer Corporation, 63 North Street, Medfield, Massachusetts 02052 □ Executive Officer □ Director ☐ General and/or Promoter ■ Beneficial Owner Check Box(s) that Apply: Managing Partner Full Name (Last name first, if individual) Farinholt, Jr., James B. Business or Residence Address (Number and Street, City, State, Zip code) Tall Oaks Capital Partners, LLC, Jefferson Building, Suite 148, 8100 Three Chopt Road, Richmond, Virginia 23229 ☐ General and/or Beneficial Owner Executive Officer Director Check Box(s) that Apply: Promoter Managing Partner

(Use blank sheet, or copy and use additional copies of this sheet, as necessary)

(Number and Street, City, State, Zip code)

Business or Residence Address

McGowan, James A.

Full Name (Last name first, if individual)

9401 Globe Center Drive, Suite 140, Morrisville, North Carolina 27560

A. BASIC IDENTIFICATION DATA 2. Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. ☐ Promoter ■ Beneficial Owner Executive Officer ☐ Director General and/or Check Box(s) that Apply: Managing Partner Full Name (Last name first, if individual) Storey, Paul T. Business or Residence Address (Number and Street, City, State, Zip code) 9401 Globe Center Drive, Suite 140, Morrisville, North Carolina 27560 ☐ General and/or Check Box(s) that Apply: ☐ Promoter ☐ Beneficial Owner Executive Officer ☐ Director Managing Partner Full Name (Last name first, if individual) Riddle, Michael D. Business or Residence Address (Number and Street, City, State, Zip code) 9401 Globe Center Drive, Suite 140, Morrisville, North Carolina 27560 ☐ Promoter ☐ Beneficial Owner ☐ Director ☐ General and/or Check Box(s) that Apply: Managing Partner Full Name (Last name first, if individual) Triscott, Mark X. Business or Residence Address (Number and Street, City, State, Zip code) 9401 Globe Center Drive, Suite 140, Morrisville, North Carolina 27560 Check Box(s) that Apply: ☐ Promoter Beneficial Owner Executive Officer Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Bayer Diagnostics Corporation Business or Residence Address (Number and Street, City, State, Zip code) 63 North Street, Medfield, Massachusetts 02052 ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer Director General and/or Check Box(s) that Apply: Managing Partner Full Name (Last name first, if individual) Johnston, Richard M. Business or Residence Address (Number and Street, City, State, Zip code) One South Street, Suite 2150, Baltimore, Maryland 21202 Check Box(s) that Apply: Promoter □ Beneficial Owner ☐ Executive Officer Director ☐ General and/or Managing Partner

Check Box(s) that Apply:

Full Name (Last name first, if individual)
Camden Partners Strategic II, LLC
Business or Residence Address (Num

Full Name (Last name first, if individual)

One South Street, Suite 2150, Baltimore, Maryland 21202

Promoter

Executive Officer

☐ Director

General and/or

Managing Partner

(Number and Street, City, State, Zip code)

Beneficial Owner

B. INFORMATION ABOUT OFFERING		
·	Yes	No
1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?		\boxtimes
Answer also in Appendix, Column 2, if filing under ULOE.		
2. What is the minimum investment that will be accepted from any individual? \$	N/A	
3. Does the offering permit joint ownership of a single unit?	Yes	No
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission		
or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such broker or dealer, you may set forth the information for that broker or dealer only.		
Full Name (Last name first, if individual)		
SG Cowen Securities Corporation		
Business or Residence Address (Number and Street, City, State, Zip Code)		
1221 Avenue of the Americas, New York, New York 10020 Name of Associated Broker or Dealer		
Name of Associated Broker of Dealer		
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers		
(Check "All States" or check individual States	\boxtimes	All States
[AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [[тн	[ID]
[MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK] [MS] OR] WY]	[MO] [PA] [PR]
Full Name (Last name first, if individual)		
Business or Residence Address (Number and Street, City, State, Zip Code)		→
Name of Associated Broker or Dealer		
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers		
(Check "All States" or check individual States		All States
[AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA]	[ні	
[IL] [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MT] [NE] [NV] [NV] [NV] [NV] [NV] [OH] [OK] [RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI]	[MS [OR [WY] [PA]
Full Name (Last name first, if individual)	·	
Business or Residence Address (Number and Street, City, State, Zip Code)		**
Name of Associated Broker or Dealer		
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers		
(Check "All States" or check individual States		All States
[AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA]	[ні	[ID]
[IL] [N] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MT] [NE] [NV] [NH] [NJ] [NM] [NV] [ND] [ND] [OH] [OK] [RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI]	[MS]	

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AN	ID.	USE OF PROCE	ED	S	
1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\sigma\) and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	<u></u>	obe of Thoca		<u> </u>	
	Type of Security		Aggregate Offering Price		A	Amount Already Sold
	Debt	\$	-	\$	i	
	Equity	\$	9,579,990	\$		9,579,990
	☐ Common ☐ Preferred	•		•		
	Convertible Securities (including warrants)	\$	0	. \$;	0
	Partnership Interests			\$		
	Other (Specify)	\$		\$	·	
	Total			\$	·	9,579,990
2.	Answer also in Appendix, Column 3, if filing under ULOE. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	•	400	•		Aggregata
			Number Investors			Aggregate Dollar Amount of Purchases
	Accredited Investors		11	\$;	9,579,990
	Non-accredited Investors		0	\$;	0
	Total (for filings under Rule 504 only)			. \$		
3.	If the filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in part C – Question 1.					
			Type of			Dollar Amount
	Type of offering		Security			Sold
	Rule 505		<u></u>	- \$; —	
	Regulation A			- \$	·	
	Rule 504			- \$	_	
	Total			- \$	· —	
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.					
	Transfer Agent's Fees			\$	·	
	Printing and Engraving Costs			\$;	
	Legal Fees		×	\$	£	175,000

□ \$

፟ \$ __

⊠ \$

⊠ \$_

622,700

20,000

817,700

Accounting Fees

Engineering Fees

Sales Commissions (specify finders' fees separately)

Other Expenses (identify: State filing fees and Nasdaq listing fee).....

Total

b. Enter the difference between the aggregate offering price given in response to Part C — Question 1 and total expenses furnished in response to Part C — Question 4.a. This difference is the "adjusted gross proceeds to the issuer". 5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C — Question 4.b above. Payments to Officers, Directors, & Affiliates Purchase of real estate. Purchase of real estate. Purchase, rental or leasing and installation of machinery and equipment. S = \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$			EDS	USE OF PROCE	AND L	RING PRICE, NUMBER OF INVESTORS, EXPENSES	C. OFFERING PRICE,
proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C – Question 4.b above. Payments to Officers, Directors, & Affiliates Salaries and fees	762,290				_	between the aggregate offering price given in response to Part C – penses furnished in response to Part C – Question 4.a. This	b. Enter the difference between the aggre Question 1 and total expenses furnished
Purchase of real estate	ayments to Others	:		Officers, Directors, &		for each of the purposes shown. If the amount for any, furnish an estimate and check the box to the left of the the payments listed must equal the adjusted gross proceeds	proposed to be used for each of the purpose is not known, furnish an esti- estimate. The total of the payments lis
Purchase, rental or leasing and installation of machinery and equipment \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$		\$			□ \$_		Salaries and fees
Construction or leasing of plant buildings and facilities		\$			□ \$_		Purchase of real estate
Construction or leasing of plant buildings and facilities		\$					
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)		\$			_		
Repayment of indebtedness \$ \$ \$ \$ \$ \$ \$ \$ \$		\$			_	nesses (including the value of securities involved in this offering ange for the assets or securities of another issuer pursuant to a	Acquisition of other businesses (including that may be used in exchange for the assets
Working capital \$ \$ \$ \$ Other (specify): \$ \$ \$ Column Totals		\$			□ \$	288	Repayment of indebtedness
Other (specify): Column Totals	8,762,290	\$	\boxtimes				
Total Payments Listed (column totals added)		\$					
The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the signature constitutes an undertaking by that issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of it information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) PharmaNetics, Inc. Date May 2003 Name of Signer (Print or Type) Title of Signer (Print or Type)	8,762,290	\$	\boxtimes		□ \$_		Column Totals
The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the signature constitutes an undertaking by that issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of it information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) PharmaNetics, Inc. Date May 1 2003 Name of Signer (Print or Type) Title of Signer (Print or Type)	<u> </u>	762,2	8,	⊠ \$		olumn totals added)	Total Payments Listed (column totals added
The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the signature constitutes an undertaking by that issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of it information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) PharmaNetics, Inc. Date May 1 2003 Name of Signer (Print or Type) Title of Signer (Print or Type)	A-0 Ha					D. FEDERAL SIGNATURE	
PharmaNetics, Inc. Name of Signer (Print or Type) Title of Signer (Print or Type) May 1 2003				nission, upon writte	Comm	is notice to be signed by the undersigned duly authorized person. taking by that issuer to furnish to the U.S. Securities and Exchang	signature constitutes an undertaking by that issu
PharmaNetics, Inc. Name of Signer (Print or Type) Title of Signer (Print or Type) May 1 2003				Date		Signate ///	Issuer (Print or Type)
		003	<u>i</u> <u>S</u> , 20	May		tilleher	PharmaNetics, Inc.
John P. Funkhouser President						President	John P. Funkhouser

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

		E. STATE	SIGNATURE			
1.	Is any party described in 17 CFR 230.252 provisions of such rule?			-	Yes □	No
	See Append	ix, Column 5, for state	response.			
2.	The undersigned issuer hereby undertakes to CFR 239.500) at such times as required by s	-	dministrator of any state	in which this notice is t	filed, a notice o	n Form D (17
3.	The undersigned issuer hereby undertakes offerees.	to furnish to the state	administrators, upon wi	ritten request, information	on furnished by	the issuer to
4.	The undersigned issuer represents that the Offering Exemption (ULOE) of the state in has the burden of establishing that these con	which this notice is fil	ed and understands that			
	e issuer has read this notification and knows ty authorized person.	the contents to be true	and has duly caused this	s notice to be signed on	its behalf by th	e undersigned
		0 0 a				
Issu	uer (Print or Type)	Stateme			Date	
	PharmaNetics, Inc.	tle	LANIX)		May <u>13</u> , 2003	
Na	me of Signer (Print or Type)	Title (Print or Type)				
	John P. Funkhouser	President				

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

APPENDIX

1	,	 2	3			4		T	5	
4.	to r accre inves State (to sell non- edited tors in Part B- m 1)	Type of security and aggregate offering price offered in state (Part C-Item 1)		Type of investor and amount purchased in State (Part C-Item 2)					
				Number of Accredited		Number of Non- Accredited				
State	Yes	No		Investors	Amount	Investors	Amount	Yes	No	
AL		1						+		
AK				· · · · · · · · · · · · · · · · · · ·				<u> </u>		
AZ								<u> </u>	1	
AR		1								
CA		X	Series B Preferred Stock (\$1,599,996)	2	\$1,599,996	0	0		Х	
СО						:				
СТ		X	Series B Preferred Stock (\$549,996)	1	\$549,996	0	0		X	
DE										
DC										
FL										
GA	!									
HI										
ID										
IL		Х	Series B Preferred Stock (\$750,000)	3	\$750,000	0	0		Х	
IN										
IA										
KS										
KY										
LA										
ME										
MD		х	Series B Preferred Stock (\$5,100,000)	2	\$5,100,000	0	0		Х	
MA										
MI										
MN										
MS										
МО										

APPENDIX

1	1	2	3			4		5		
•	to r accre invest State (to sell non- edited tors in Part B— n 1)	Type of security and aggregate offering price offered in state (Part C-Item 1)		Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)					
State	Yes	No		Number of Accredited Investors	Amount	Number of Non- Accredited Investors	Amount	Yes	No	
MT										
NE							·			
NV										
NH				Telepological de la constantina della constantin						
NJ										
NM										
NY		Х	Series B Preferred Stock (\$1,579,998)	3	\$1,579,998	0	0		Х	
NC										
ND										
ОН										
OK										
OR										
PA				-			10.4			
RI										
SC										
SD										
TN										
TX										
UT										
VT										
VA										
WA										
wv						:				
WI										
WY										
PR										